Cellular therapy for ocular degeneration

• US 9,074,189 B2
• Filed: 06/02/2006
• Issued: 07/07/2015
• Est. Priority Date: 06/08/2005
• Status: Expired due to Fees

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Mistry, Sanjay
• Primary Examiner(s): WANG, CHANG YU
• Application Number:
  US11/446,462
• Publication Number:
  US 20060280729A1
• Time in Patent Office: 3,322 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 27/12 for cataracts
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources

Abstract

Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45.

Claims

1. A method of treating a patient having retinitis pigmentosa, the method comprising administering to the patient mesenchymal stem cells in an amount effective to treat the retinitis pigmentosa, wherein the mesenchymal stem cells are characterized by the expression of CD105, and the lack of expression of CD34, and wherein the mesenchymal stem cells promote the survival of ocular cells, or the formation of photoreceptors from ocular cells in situ, but the mesenchymal stem cells do not form structures similar to the photoreceptor layer and do not express a photoreceptor-specific marker;

or do not differentiate into photoreceptors themselves.

2. The method of claim 1, wherein the cells are administered to the surface of an eye.

3. The method of claim 1, wherein the cells are administered to the interior of an eye.

4. The method of claim 3, wherein the cells are administered through a cannula or from a device implanted in the patient'"'"'s body within or in proximity to the eye.

5. The method of claim 3, wherein the cells are administered by implantation of a three dimensional matrix or support containing the cells.

6. The method of claim 3, wherein the method comprises administration of a pharmaceutical composition comprising the cells and a pharmaceutically acceptable carrier.

7. The method of claim 6, wherein the pharmaceutical composition is formulated for administration to the surface of an eye.

8. The method of claim 6, wherein the pharmaceutical composition is formulated for administration to the interior of an eye.